MovDisordV3, PubMed, Corpus, bibRecord, 003120

Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.

Identifieur interne : 003120 ( PubMed/Corpus ); précédent : 003119; suivant : 003121

Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.

Auteurs : Antonio L. Teixeira ; Melissa M. Guimarães ; Marco Aurélio Romano-Silva ; Francisco Cardoso

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.

RBID : pubmed:15747354

English descriptors

KwdEn :
- Adolescent, Animals, Antibodies (pharmacology), Basal Ganglia (immunology), Calcium (metabolism), Child, Chorea (blood), Chorea (immunology), Complement System Proteins (pharmacology), Enzyme-Linked Immunosorbent Assay (methods), Female, Humans, Intracellular Fluid (metabolism), Microscopy, Confocal (methods), PC12 Cells (drug effects), Potassium Chloride (pharmacology), Rats, Serum (metabolism).
MESH :
- chemical , metabolism : Calcium.
- chemical , pharmacology : Antibodies, Complement System Proteins, Potassium Chloride.
- blood : Chorea.
- drug effects : PC12 Cells.
- immunology : Basal Ganglia, Chorea.
- metabolism : Intracellular Fluid, Serum.
- methods : Enzyme-Linked Immunosorbent Assay, Microscopy, Confocal.
- Adolescent, Animals, Child, Female, Humans, Rats.

Abstract

The proposed pathogenesis of Sydenham's chorea (SC) is an autoantibody-mediated basal ganglia dysfunction. Our study has shown that incubation of PC12 cells with complement-inactivated serum from SC patients was associated with a significant increase in Ca2+ levels evoked by KCl stimulus (mean +/- SEM, 341.0 +/- 8.7% of fluorescence intensity, arbitrary units) when compared with incubation with control serum (313.8 +/- 8.7% of fluorescence intensity, arbitrary units; P = 0.01). The increase in Ca2+ levels determined by SC patients sera correlated directly with the enzyme-linked immunosorbent assay optical density values for anti-basal ganglia antibodies. Our study supports the hypothesis that antibodies against basal ganglia in SC may cause their dysfunction.

DOI: 10.1002/mds.20418
PubMed: 15747354

Links to Exploration step

pubmed:15747354

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.</title>
<author><name sortKey="Teixeira, Antonio L" sort="Teixeira, Antonio L" uniqKey="Teixeira A" first="Antonio L" last="Teixeira">Antonio L. Teixeira</name>
<affiliation><nlm:affiliation>Movement Disorders Clinic, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Guimaraes, Melissa M" sort="Guimaraes, Melissa M" uniqKey="Guimaraes M" first="Melissa M" last="Guimarães">Melissa M. Guimarães</name>
</author>
<author><name sortKey="Romano Silva, Marco Aurelio" sort="Romano Silva, Marco Aurelio" uniqKey="Romano Silva M" first="Marco Aurélio" last="Romano-Silva">Marco Aurélio Romano-Silva</name>
</author>
<author><name sortKey="Cardoso, Francisco" sort="Cardoso, Francisco" uniqKey="Cardoso F" first="Francisco" last="Cardoso">Francisco Cardoso</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="doi">10.1002/mds.20418</idno>
<idno type="RBID">pubmed:15747354</idno>
<idno type="pmid">15747354</idno>
<idno type="wicri:Area/PubMed/Corpus">003120</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.</title>
<author><name sortKey="Teixeira, Antonio L" sort="Teixeira, Antonio L" uniqKey="Teixeira A" first="Antonio L" last="Teixeira">Antonio L. Teixeira</name>
<affiliation><nlm:affiliation>Movement Disorders Clinic, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Guimaraes, Melissa M" sort="Guimaraes, Melissa M" uniqKey="Guimaraes M" first="Melissa M" last="Guimarães">Melissa M. Guimarães</name>
</author>
<author><name sortKey="Romano Silva, Marco Aurelio" sort="Romano Silva, Marco Aurelio" uniqKey="Romano Silva M" first="Marco Aurélio" last="Romano-Silva">Marco Aurélio Romano-Silva</name>
</author>
<author><name sortKey="Cardoso, Francisco" sort="Cardoso, Francisco" uniqKey="Cardoso F" first="Francisco" last="Cardoso">Francisco Cardoso</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Animals</term>
<term>Antibodies (pharmacology)</term>
<term>Basal Ganglia (immunology)</term>
<term>Calcium (metabolism)</term>
<term>Child</term>
<term>Chorea (blood)</term>
<term>Chorea (immunology)</term>
<term>Complement System Proteins (pharmacology)</term>
<term>Enzyme-Linked Immunosorbent Assay (methods)</term>
<term>Female</term>
<term>Humans</term>
<term>Intracellular Fluid (metabolism)</term>
<term>Microscopy, Confocal (methods)</term>
<term>PC12 Cells (drug effects)</term>
<term>Potassium Chloride (pharmacology)</term>
<term>Rats</term>
<term>Serum (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Calcium</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies</term>
<term>Complement System Proteins</term>
<term>Potassium Chloride</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Chorea</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>PC12 Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Basal Ganglia</term>
<term>Chorea</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Intracellular Fluid</term>
<term>Serum</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term>
<term>Microscopy, Confocal</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Animals</term>
<term>Child</term>
<term>Female</term>
<term>Humans</term>
<term>Rats</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The proposed pathogenesis of Sydenham's chorea (SC) is an autoantibody-mediated basal ganglia dysfunction. Our study has shown that incubation of PC12 cells with complement-inactivated serum from SC patients was associated with a significant increase in Ca2+ levels evoked by KCl stimulus (mean +/- SEM, 341.0 +/- 8.7% of fluorescence intensity, arbitrary units) when compared with incubation with control serum (313.8 +/- 8.7% of fluorescence intensity, arbitrary units; P = 0.01). The increase in Ca2+ levels determined by SC patients sera correlated directly with the enzyme-linked immunosorbent assay optical density values for anti-basal ganglia antibodies. Our study supports the hypothesis that antibodies against basal ganglia in SC may cause their dysfunction.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15747354</PMID>
<DateCreated><Year>2005</Year>
<Month>07</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted><Year>2005</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>20</Volume>
<Issue>7</Issue>
<PubDate><Year>2005</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.</ArticleTitle>
<Pagination><MedlinePgn>843-5</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The proposed pathogenesis of Sydenham's chorea (SC) is an autoantibody-mediated basal ganglia dysfunction. Our study has shown that incubation of PC12 cells with complement-inactivated serum from SC patients was associated with a significant increase in Ca2+ levels evoked by KCl stimulus (mean +/- SEM, 341.0 +/- 8.7% of fluorescence intensity, arbitrary units) when compared with incubation with control serum (313.8 +/- 8.7% of fluorescence intensity, arbitrary units; P = 0.01). The increase in Ca2+ levels determined by SC patients sera correlated directly with the enzyme-linked immunosorbent assay optical density values for anti-basal ganglia antibodies. Our study supports the hypothesis that antibodies against basal ganglia in SC may cause their dysfunction.</AbstractText>
<CopyrightInformation>Copyright 2005 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teixeira</LastName>
<ForeName>Antonio L</ForeName>
<Initials>AL</Initials>
<Suffix>Jr</Suffix>
<AffiliationInfo><Affiliation>Movement Disorders Clinic, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Guimarães</LastName>
<ForeName>Melissa M</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Romano-Silva</LastName>
<ForeName>Marco Aurélio</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cardoso</LastName>
<ForeName>Francisco</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>660YQ98I10</RegistryNumber>
<NameOfSubstance UI="D011189">Potassium Chloride</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9007-36-7</RegistryNumber>
<NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber>
<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000906">Antibodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002819">Chorea</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003165">Complement System Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004797">Enzyme-Linked Immunosorbent Assay</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007424">Intracellular Fluid</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018613">Microscopy, Confocal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016716">PC12 Cells</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011189">Potassium Chloride</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D044967">Serum</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>11</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.20418</ArticleId>
<ArticleId IdType="pubmed">15747354</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003120 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003120 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:15747354
   |texte=   Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:15747354" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.

Serum from Sydenham's chorea patients modifies intracellular calcium levels in PC12 cells by a complement-independent mechanism.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki